Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx) - EMG

Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)

Oncology

At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincent’s University Hospital, Dublin, Ireland, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx). TAILORx is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, node-negative breast cancer whose treatment was guided by the Oncotype DX® Breast Cancer Assay Recurrence Score® results. The results showed that adding genomic information provided by the Oncotype DX® Breast Cancer Assay may influence the selection of patients for adjuvant chemotherapy based on standard clinicopathological criteria.

This content is supported by Genomic Health, Inc.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given